Your browser doesn't support javascript.
loading
Treatment options for older unfit patients with acute myeloid leukemia.
Tang, Hailong; Jia, Shuangshuang; Bi, Lei; Jia, Weijing; Gao, Guangxun.
Afiliación
  • Tang H; Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
  • Jia S; Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
  • Bi L; Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
  • Jia W; Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
  • Gao G; Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Future Oncol ; 17(7): 837-851, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33522289
Older acute myeloid leukemia patients usually experience a bleak outcome, especially those in the unfit group. For this unfit category, intensive chemotherapy and allogeneic stem cell transplantation are usually accompanied by higher early mortality, which results from higher risk genetic profiles and worse psychological and physiological conditions. The significant improvement in genetic technology recently has driven the appearance of several mutation-targeted therapies, such as FLT3, Bcl-2, IDH and Hedgehog pathway inhibitors and an anti-CD33 antibody-drug conjugate, which have changed enormously the therapeutic landscape of acute myeloid leukemia. This review describes the treatment dilemma of the unfit group and discusses the objective clinical data of each targeted drug and mechanisms of resistance, with a focus on combination strategies with fewer toxicities and abrogation of drug resistance.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor Tipo de estudio: Diagnostic_studies Límite: Aged / Aged80 / Humans Idioma: En Revista: Future Oncol Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor Tipo de estudio: Diagnostic_studies Límite: Aged / Aged80 / Humans Idioma: En Revista: Future Oncol Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido